Arca
Skip to content
Tools
Tools

TXNRD1: Thioredoxin reductase 1, cytoplasmic

Reduces disulfide protein thioredoxin (Trx) to its dithiol- containing form.

  • Drugs that act on it: 3
  • Approved: 2
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on TXNRD1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved2

  • Arsenic trioxide
  • Aurothioglucose

Phase 31

  • Motexafin gadolinium

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Thioredoxin reductase 1 inhibitor.
      Arsenic trioxideBoxed warningApprovedTeva Pharmaceutical IndustriesSmall moleculeInhibitor18
      AurothioglucoseApproved—Small moleculeInhibitor1
      Motexafin gadoliniumPhase 3AbbVieSmall moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
      Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant MedulloblastomaArsenic trioxidePhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOct 2, 2026
      Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic SyndromeArsenic trioxidePhase 1RecruitingUniversity of Michigan Rogel Cancer CenterJul 30, 2026
      Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaArsenic trioxidePhase 3RecruitingQuetzal TherapeuticsMar 31, 2026
      ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.Arsenic trioxidePhase 1Not yet recruitingDaniel BreadnerJan 16, 2026
      A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)Arsenic trioxidePhase 3Not yet recruitingSDK Therapeutics, Inc.Dec 22, 2025
      Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaArsenic trioxideNot applicableActive, not recruitingAnhui Medical UniversitySep 23, 2025
      Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M NeuroblastomaArsenic trioxidePhase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityApr 18, 2025
      Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsAurothioglucosePhase 2RecruitingFederal University of São PauloFeb 3, 2025
      Oral-ATO for TP53-mutated Myeloid MalignanciesArsenic trioxidePhase 2RecruitingThe University of Hong KongJan 16, 2025

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1927, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt Q16881, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.